Hylan G-F 20 single-injection formulation

Drugs and Aging

Volumn 27, Issue 1, 2010, Pages 77-85

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Hylan G F 20, pharmacodynamics; Hylan G F 20, pharmacokinetics; Hylan G F 20, therapeutic use; Osteoarthritis, treatment

Indexed keywords

HYALURONIC ACID DERIVATIVE; HYLAN G F 20; SYNVISC ONE; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BACKACHE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HEADACHE; HEMATOMA; HUMAN; INFLUENZA; INJECTION SITE PAIN; JOINT EFFUSION; KNEE OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SYNCOPE;

CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; PAIN; PAIN MEASUREMENT;

EID: 73849136310     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11203900-000000000-00000     Document Type: Review

References (20)

1. Yang LPH, Perry CM. Zonisamide: in Parkinson's disease. CNS Drugs 2009; 23 (8): 703-711
2. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006 Jun; 5 (6): 525-535
3. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004 May 29; 363 (9423): 1783-1793
4. Lew M. Overview of Parkinson's disease. Pharmacotherapy 2007 Dec; 27 (12 Pt 2): 155S-60S
5. Yamawaki M, Kusumi M, Kowa H, et al. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century.Neuroepidemiology 2009; 32 (4): 263-269
6. Greenamyre JT, Hastings TG. Parkinson's: divergent causes, convergent mechanisms. Science 2004 May 21; 304 (5674): 1120-1122
7. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007 Dec; 27 (12 Pt 2): 161S-73S
8. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35) [online]. Available from URL: http://www.nice.org.uk/nicemedia/ pdf/cg035niceguideline.pdf [Accessed 2009 Feb 19]
9. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66 (7): 983-995
10. Excegran (zonisamide) 100 mg tablets, 20% powder: prescribing information. Osaka: Dainippon Pharmaceutical Co., Ltd, 2004 Apr
11. US FDA. Zonegran- (zonisamide) capsules:US prescribing information [online]. Available fromURL: http://www.fda.gov/cder/foi/label/2006/ 020789s019lbl.pdf [Accessed 2009 Mar 6]
12. European Medicines Agency. Zonegran (zonisamide) 25, 50 or 100mg hard capsules: summary of product characteristics [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/zonegran/emea-combin ed-h577en.pdf [Accessed 2009 May 20]
13. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001 Dec; 41 (4): 397-399
14. Trerief (zonisamide) 25 mg tablets: prescribing information [in Japanese]. Osaka: Dainippon Sumitomo Pharma Co., Ltd, 2009 Feb
15. BitonV.Clinical pharmacology andmechanism of action of zonisamide. Clin Neuropharmacol 2007 Jul-Aug; 30 (4): 230-240
16. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release. Epilepsy Res 1992 Nov; 13 (2): 113-119
17. OkadaM,Kaneko S,Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995Nov; 22 (3): 193-205
18. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. The Japan Zonisamide on PD Study Group [published erratum appears in: Neurology 2007 Jul 3; 69 (1): 20].
19. Neurology 2007 Jan 2; 68 (1): 45-50
20. Data on file [in Japanese], Dainippon Sumitomo Pharma Co., Ltd, 2009